Clinical Trials Logo

Clinical Trial Summary

Primary objectives are to evaluate the safety profile and tolerability of oral BCX1777 in each cohort of patients with recurrent or refractory T/NK-cell malignancies and to evaluate pharmacokinetics (PK) of oral BCX1777.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Neoplasms
  • Recurrent or Refractory T/NK-cell Malignancies

NCT number NCT00823355
Study type Interventional
Source Mundipharma K.K.
Contact
Status Completed
Phase Phase 1
Start date January 2009